Evidence map›Paper›PMID 28367485›Full record

ArticleData in brief2017

Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel.

Voin Petrovic, Camilla Olaisen, Animesh Sharma, Anala Nepal, Steffen Bugge, Eirik Sundby, Bård Helge Hoff, Geir Slupphaug, Marit Otterlei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Data in brief, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Voin PetrovicDepartment of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Camilla OlaisenDepartment of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Animesh SharmaThe Proteomics and Metabolomics Core Facility (PROMEC) at NTNU, Faculty of Medicine, Trondheim, Norway.
Anala NepalDepartment of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Steffen BuggeDepartment of Chemistry, Faculty of Natural Sciences and Technology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Eirik SundbyDepartment of Chemistry and Material Technology, Faculty of Natural Sciences and Technology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Bård Helge HoffDepartment of Chemistry, Faculty of Natural Sciences and Technology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Geir SlupphaugThe Proteomics and Metabolomics Core Facility (PROMEC) at NTNU, Faculty of Medicine, Trondheim, Norway.
Marit OtterleiDepartment of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell extracts from A549, H460, and U2OS human cancer cell lines treated with cisplatin and docetaxel were analyzed by mass spectrometry (MS) proteomic analysis. The extracts were enriched for cellular signaling proteins using a mix of three different immobilized kinase inhibitors (Purvalanol B, Bisindolylmaleimide X, and (R)-3-(4-((1-Phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzoic acid (SB6-060-05)) on sepharose bead columns. Raw data is deposited in the PRIDE database [1], project number PXD005286. Data presented () shows changes relative to untreated control for each biological replicate for the three cell lines.

Identifiers

PMID28367485
PMCPMC5362150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.